The Expanded Disability Status Scale (EDSS) and the Functional Systems Score (FSS) together describe severity of disability in patients with MS. With the help of the FSS, the examiner rates your disability on the EDSS scale. It ranges from 0 to 10, with half points for greater specificity. EDSS. • Expanded Disability Status Scale. – Devised by John Kurtzke in the s and modified A modification of the original Kurtzke scale.

Author: Satilar Samugis
Country: Cayman Islands
Language: English (Spanish)
Genre: Photos
Published (Last): 25 June 2010
Pages: 94
PDF File Size: 13.33 Mb
ePub File Size: 6.70 Mb
ISBN: 219-3-99969-806-1
Downloads: 29915
Price: Free* [*Free Regsitration Required]
Uploader: Kazil

The choose of medication changes from drug availability, introduction of new drugs in the market, Government shdet or preference for one of the several physicians in charge of patients over the years.

The data were analyzed using descriptive statistical methods such as the Student “t” test, Pearson’s correlation, Mann-Whitney U test and Wilcoxon signed ranks test. In situations when there is subjectivity and FS deficits do not correspond to a specific EDSS level, a range is provided. Up and about in wheelchair some 12 hours csore day 7. Relapses were treated in a subgroup of patients by corticosteroid administration, which took the form of either intravenous methylprednisolone pulse therapy or oral prednisone.

Moderate nystagmus or other mild disability. The positive correlation of the EDSS with time of treatment and some sub-groups could be interpreted as progression of disability, while the negative correlation could be reduction or stabilization.

Unable to take more than a few steps. Please fill out required fields. The difference in the time of treatment for each group probably occurred because of the following reasons: The variation between the initial and final EDSS scores showed a reduction in 43 patients The other authors declare that they have no conflicts of interest.

Acta Neurol Scand ; Vibration or figure-writing decrease only, in limbs. This SYT group included newly diagnosed cases that had experienced a remission in clinical symptoms, a good therapeutic response to prednisone or methylprednisolone during relapses, a long interval between the second and third relapse, or side effects from other medications off IMS or IMM more than three months to be included in this groupor were from a period before the availability of IMM drugs or refused to use prescribed medications.


Abnormal signs without disability.

The interferon beta-1b years long-term follow-up study: Mild or moderate paraparesis or hemiparesis; severe monoparesis. Med treatment and more Treatment. Rating neurologic impairment in multiple sclerosis: Multiple sclerosis severity score: A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Comparison of glatiramer acetate Copaxone and interferon beta-1b Betaferon in multiple sclerosis patients: The major difficulty find consistent data on long term efficacy of IMS or IMS is to follow patients for a long period of time, because most clinical trials have a short duration 2 to 4 years or the degrees of disability are too small and it is not possible to conclude or measure if potential therapeutic options are effective after a long period He was a leading expert in the study of multiple sclerosis MS and a contributor in the creation of the field of neuroepidemiology.

Advice Use to measure progression of disease in MS patients. The scoring is based on an examination by a neurologist but is also useful for you to measure where your disease may currently be in as far as the progression scale indicates. The final EDSS score showed variation for the reduction of disability up to four points and increased until five points, and a similar variation occurred with several IMM drugs 7. The EDSS scale is not a defacto mechanism but instead a fairly simplistic means and mechanism to measure MS disability rather broadband.

These drugs were not considered as a unique treatment group, because steroid administration was used in all groups during exacerbation.

Mitoxantrone as induction treatment in aggressive relapsing multiple sclerosis: Inability to swallow or speak. Or create a new account it’s free. In this study series, no statistical difference was found in the long-term progression of disability among the IMS and IMM treated cases, nor in the cases treated only with corticosteroids. Moderate truncal or limb ataxia. Mood alteration only Does not affect DSS score. Management of worsening multiple sclerosis with mitoxantrone: We evaluated the progression of disability using the EDSS score 24 because this index can be recorded based on the clinical manifestation and neurological examination recorded in the past decades.


Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: The hseet Pearson between the final EDSS and time of disease progression for the whole group was 0.

Expanded Disability Status Scale (EDSS) | MS Unites – Multiple Sclerosis (MS) Information Portal

J Neurol Sci ; No statistically significance difference was found in the MSSS between initial and final scores in the whole group or treatment sub-groups. MRI as an outcome in multiple sclerosis clinical trials. Some cases stabilized and even sheet a reduction in long-term disability, according the type of scale used. Each functional aspect is scored on a scale of 0 no disability to 5 or 6 more severe disability.

Expanded Disability Status Scale (EDSS)

Another study that used BET over a period of 16 years also showed a progression in disability, but demonstrated that individuals achieved the same degree of disability when using the medication for a period of 4.

Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.

The sample consisted of patients female and 37 male with an age edss ranging from 12 to 55 years median More recently, a new score was developed based on the initial EDSS score and the time of disease progression for each patient.

Author: admin